MRC Pandemic Preparedness Funding - The Francis Crick Institute

Key facts

Disease
COVID-19
Start & end year
2021
2021
Known Financial Commitments (USD)
$1,688,850
Funder
UK Research and Innovation (UKRI)
Principal Investigator
N/A
Research Location
United Kingdom
Lead Research Institution
The Francis Crick Institute
Research Priority Alignment
N/A

Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

This funding will enable the Institute to address two major aims: i) understanding the coronavirus pathogen, including viral assembly, host factors and exploitation of structural components for the development of therapeutic targets; ii) understanding the features of host response to infection that shape protective or pathological responses and defining correlates of immunity and immune pathology.

41 Publications linked via Europe PMC

Last Updated:6 days ago

View all publications at Europe PMC

WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed.

SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies.

Three-dose vaccination elicits neutralising antibodies against omicron.

Evolution of the SARS-CoV-2 spike protein in the human host.

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.

Authors
Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, Cerrone M, Schmitt AM, Joharatnam-Hogan N, Shum B, Tippu Z, Rzeniewicz K, Boos LA, Harvey R, Carlyle E, Edmonds K, Del Rosario L, Sarker S, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Bazin J, Gordon W, Barber T, Emslie-Henry A, Xie W, Gerard CL, Deng D, Wall EC, Agua-Doce A, Namjou S, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Dowdie L, Ash N, Gronthoud F, Shea RL, Gardner G, Murray D, Kinnaird F, Cui W, Pascual J, Rodney S, Mencel J, Curtis O, Stephenson C, Robinson A, Oza B, Farag S, Leslie I, Rogiers A, Iyengar S, Ethell M, Messiou C, Cunningham D, Chau I, Starling N, Turner N, Welsh L, van As N, Jones RL, Droney J, Banerjee S, Tatham KC, O'Brien M, Harrington K, Bhide S, Okines A, Reid A, Young K, Furness AJS, Pickering L, Swanton C, Crick COVID-19 Consortium, Gandhi S, Gamblin S, Bauer DLV, Kassiotis G, Kumar S, Yousaf N, Jhanji S, Nicholson E, Howell M, Walker S, Wilkinson RJ, Larkin J, Turajlic S, CAPTURE Consortium.
Publish Year
2021
Journal
Nature cancer
DOI
10.1038/s43018-021-00274-w

View at Europe PMC

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.

Authors
Fendler A, Shepherd STC, Au L, Wu M, Harvey R, Schmitt AM, Tippu Z, Shum B, Farag S, Rogiers A, Carlyle E, Edmonds K, Del Rosario L, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Barber T, Emslie-Henry A, Caulfield-Lynch N, Byrne F, Deng D, Kjaer S, Song OR, Queval C, Kavanagh C, Wall EC, Carr EJ, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Shea RL, Gardner G, Murray D, Yousaf N, Jhanji S, Tatham K, Cunningham D, Van As N, Young K, Furness AJS, Pickering L, Beale R, Swanton C, Gandhi S, Gamblin S, Bauer DLV, Kassiotis G, Howell M, Nicholson E, Walker S, Larkin J, Turajlic S, CAPTURE consortium.
Publish Year
2022
Journal
Lancet (London, England)
DOI
10.1016/s0140-6736(22)00147-7

View at Europe PMC

Defining Potential Therapeutic Targets in Coronavirus Disease 2019: A Cross-Sectional Analysis of a Single-Center Cohort.

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.

Authors
Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Schmitt AM, Tippu Z, Farag S, Rogiers A, Harvey R, Carlyle E, Edmonds K, Del Rosario L, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Barber T, Emslie-Henry A, Caulfield-Lynch N, Byrne F, Shum B, Gerard CL, Deng D, Kjaer S, Song OR, Queval C, Kavanagh C, Wall EC, Carr EJ, Namjou S, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Shea RL, Gardner G, Murray D, Yousaf N, Jhanji S, Van As N, Young K, Furness AJS, Pickering L, Beale R, Swanton C, Crick COVID19 consortium, Gandhi S, Gamblin S, Bauer DLV, Kassiotis G, Howell M, Nicholson E, Walker S, Wilkinson RJ, Larkin J, Turajlic S, CAPTURE consortium.
Publish Year
2022
Journal
Cancer cell
DOI
10.1016/j.ccell.2021.12.013

View at Europe PMC

MRC Pandemic Preparedness Funding - The Francis Crick Institute

Key facts

Abstract

41 Publications linked via Europe PMC

WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed.

SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies.

Three-dose vaccination elicits neutralising antibodies against omicron.

Evolution of the SARS-CoV-2 spike protein in the human host.

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.

Defining Potential Therapeutic Targets in Coronavirus Disease 2019: A Cross-Sectional Analysis of a Single-Center Cohort.

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.